TY - JOUR T1 - Three ALS genes regulate expression of the MHC class II antigen presentation pathway JF - bioRxiv DO - 10.1101/2022.05.11.489680 SP - 2022.05.11.489680 AU - Binkai Chi AU - Muhammet M. Öztürk AU - Christina L. Paraggio AU - Claudia E. Leonard AU - Maria E. Sanita AU - Mahtab Dastpak AU - Jeremy D. O’Connell AU - Jordan A. Coady AU - Jiuchun Zhang AU - Steven P. Gygi AU - Rodrigo Lopez-Gonzalez AU - Robin Reed Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/05/11/2022.05.11.489680.abstract N2 - Here we report that the major histocompatibility complex II (MHC II) antigen presentation pathway is regulated by the ALS-causative genes, FUS, TAF15, or MATR3. Of >6000 proteins detected by quantitative mass spectrometry, the subunits of the MHC II heterodimer, HLA-DR, were the top 2 downregulated proteins in HeLa knock outs (KO) of these ALS genes, but not the related gene, EWSR1. Moreover, CD74, which is the 3rd essential component of HLA-DR, was downregulated in the 3 KOs. We show that the downregulations are due to loss of CIITA, a transcription factor dedicated to expression of MHC II genes. Thus, our results reveal the 1st shared cellular pathway regulated by multiple ALS genes, and this pathway is ALS genes -> CIITA -> MHC II genes. We obtained the same results in HMC3 cells, a microglia cell line, showing that loss of the MHC II pathway extends to an ALS-relevant cell type in the central nervous system (CNS). Furthermore, the MHC II pathway is downregulated in hematopoietic progenitor cells (HPCs) bearing the ALS FUSR495X mutation. This observation may be highly significant to ALS pathogenesis as HPCs give rise to a multitude of CNS-specific and systemic immune cells, both of which have known or suspected roles in ALS. Together, our data raise the possibility that loss of the MHC II pathway in a large range of immune cells results in global failure of the immune system to protect motor neurons from damage that leads to the disease. Consequently, CIITA and the other genes in the MHC II pathway may be important new therapeutic targets for the disease.Competing Interest StatementThe authors have declared no competing interest. ER -